FY2026 Earnings Estimate for CVRx Issued By William Blair

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Analysts at William Blair issued their FY2026 earnings per share estimates for CVRx in a research report issued on Friday, December 13th. William Blair analyst M. Andrew forecasts that the company will post earnings per share of ($1.91) for the year. The consensus estimate for CVRx's current full-year earnings is ($2.62) per share.

CVRX has been the topic of a number of other reports. Craig Hallum raised their target price on shares of CVRx from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. Piper Sandler reiterated an "overweight" rating and set a $16.00 price target (up from $13.00) on shares of CVRx in a report on Wednesday, October 30th. Cantor Fitzgerald reissued an "overweight" rating and set a $14.00 price objective on shares of CVRx in a research report on Wednesday, October 23rd. Lake Street Capital increased their target price on shares of CVRx from $12.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group raised their target price on shares of CVRx from $17.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, CVRx presently has an average rating of "Moderate Buy" and a consensus target price of $16.67.

CVRx Stock Performance

CVRx stock traded up $0.55 during midday trading on Monday, hitting $13.38. The stock had a trading volume of 159,043 shares, compared to its average volume of 271,202. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. CVRx has a 52-week low of $6.40 and a 52-week high of $33.13. The firm's fifty day moving average is $12.60 and its two-hundred day moving average is $10.45. The company has a market capitalization of $324.65 million, a PE ratio of -4.75 and a beta of 1.20.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The business had revenue of $13.37 million for the quarter, compared to analysts' expectations of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period last year, the firm posted ($0.43) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CVRX. Bank of New York Mellon Corp raised its position in shares of CVRx by 30.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,191 shares of the company's stock worth $446,000 after acquiring an additional 8,741 shares in the last quarter. Rhumbline Advisers lifted its position in CVRx by 28.8% in the 2nd quarter. Rhumbline Advisers now owns 17,260 shares of the company's stock worth $207,000 after buying an additional 3,863 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in CVRx in the 2nd quarter worth approximately $218,000. Marshall Wace LLP bought a new stake in shares of CVRx in the second quarter worth about $495,000. Finally, Squarepoint Ops LLC boosted its stake in shares of CVRx by 26.3% during the 2nd quarter. Squarepoint Ops LLC now owns 91,999 shares of the company's stock valued at $1,103,000 after purchasing an additional 19,165 shares in the last quarter. 75.27% of the stock is owned by institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.